Avidity touts early data, showing positive effect on progressive muscular disease while under partial FDA hold
An RNA biotech is looking to tout Phase I/II data as investors sent its share price on a rebound.
Avidity Biosciences said Wednesday that its candidate, AOC 1001, successfully targeted siRNA to muscle in a bid to address the root cause behind a disease known as myotonic dystrophy type 1, or DM1. The disease, a genetic disorder that causes progressive muscle weakness, affects more than 40,000 people in the US, where there is no approved therapy.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.